T3P-Y058-739 / Boehringer Ingelheim - LARVOL DELTA

First in Human Study of T3P-Y058-739 (T3P) (clinicaltrials.gov) - P1/2 | N=100 | Recruiting | Sponsor: T3 Pharmaceuticals AG | Trial completion date: Oct 2026 ➔ Oct 2027 | Trial primary completion date: Feb 2026 ➔ Feb 2027

Trial completion date • Trial primary completion date • Gastrointestinal Disorder • Oncology • Solid Tumor

First in Human Study of T3P-Y058-739 (T3P) (clinicaltrials.gov) - P1/2 | N=100 | Recruiting | Sponsor: T3 Pharmaceuticals AG | Trial completion date: Feb 2025 ➔ Oct 2026 | Trial primary completion date: Oct 2024 ➔ Feb 2026

Metastases • Trial completion date • Trial primary completion date • Gastrointestinal Disorder • Oncology • Solid Tumor

First in Human Study of T3P-Y058-739 (T3P) (clinicaltrials.gov) - P1/2 | N=100 | Recruiting | Sponsor: T3 Pharmaceuticals AG | Not yet recruiting ➔ Recruiting

Enrollment open • Gastrointestinal Disorder • Oncology • Solid Tumor

First in Human Study of T3P-Y058-739 (T3P) (clinicaltrials.gov) - P1/2; N=100; Not yet recruiting; Sponsor: T3 Pharmaceuticals AG

Clinical • New P1/2 trial • Gastrointestinal Disorder • Oncology • Solid Tumor